Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golidocitinib Monotherapy for Hemophagocytic Lymphohistiocytosis
NCT07339345Phase 3Recruiting
- Sponsor
- Beijing Friendship Hospital
- Start
- Jun 2025
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of golidocitinib in hemophagocytic lymphohistiocytosis (HLH), sponsored by Beijing Friendship Hospital. Started Jun 2025; status: recruiting.
02
Drugs
golidocitinib
03
Conditions
hemophagocytic lymphohistiocytosis (HLH)
Beyond the preview
Go deeper on NCT07339345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07339345.